Valuation: Kadimastem

Market Cap 51.86M 0 16.81M 14.93M 13.96M 12.72M 23.95M 1.62B 24.28M 169M 65.38M 824M 63.11M 61.74M 2.65B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 51.86M 0 16.81M 14.93M 13.96M 12.72M 23.95M 1.62B 24.28M 169M 65.38M 824M 63.11M 61.74M 2.65B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
32.43%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-8.93% - - 16.81M
+4.16%+3.04%+49.37%+94.17% 74.41B
-1.19%-1.63%+24.31%+78.03% 59.26B
-0.18%-1.83%+3.02%+32.89% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-3.21%+2.36%+28.92%+22.05% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.66%-0.52%+52.60%+153.80% 43.6B
Weighted average by Cap. -0.19%-0.32%+57.79%+145.49%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Kadimastem
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
Employees
11